Member Info for bunsenburner123

I just sold the last of mine £40k. Probs see 44p this week though. Hoping for 39.5p and I’ll grab them back

Let the rerate begin now

Overhang gone

Dilution risk gone

PR and media ramp up next few weeks

Much more concrete update of late, mixed with debt restructure, CLNs at 30p convert to equity. Dara on the board, huge discount to the placing. It’s just clearly a way cheaper and better proposition now, IMO of course

The wording difference is actually quite important.

The earlier 2025 update was more:

* optimistic,

* forward-looking,

* and based around momentum and “run rates.”

The newer Q1 2026 update was more:

* operational,

* concrete,

* and profitability-focused.

That’s the key distinction.

Earlier RNS wording (more promotional/aspirational)

Things like:

“positive EBITDA run rate”

That does NOT necessarily mean:

* the company itself was EBITDA positive overall.

It can mean:

* one month,

* one division,

* exit rate,

* or adjusted trajectory.

Also phrases like:

* “strong momentum”

* “ahead of budget”

* “confident outlook”

* “high-margin opportunities”

* “growth trajectory”

are common AIM growth-company language.

Importantly:

that RNS did NOT explicitly say:

* “the business traded profitably.”

Newer Q1 2026 wording (materially stronger)

The newer update says directly:

“The Company has achieved positive EBITDA in Q1 2026”

and

“marking the first reporting period that it has traded profitably”

That is MUCH stronger wording.

They also quantified:

* £700k EBITDA improvement YoY

and added:

“expects this positive EBITDA performance to continue”

plus:

“anticipates the business will be cash flow positive from the end of Q2 onwards”

Fair but a few key points -

SP at that time was between 60p and 35p. Now it’s 22p. They’ve also raised and restructured all the debt £3m at 30p again way cheaper now. Also, see the next post on the clear difference in language from the two RNSs:

Let’s hope the volume starts picking up. If and when it does and this placing clears things could get v exciting

The v interesting thing to look out for now will be the TR1s. Let’s see who took all the shares. Significantly oversubscribed I’d imagine we get some new TR1s

Let’s be honest that’s amazing news

Significant grant potential

I’m in this for the medium term and the investment case just got super super bullish

Massively well funded and on grant receipt this will look like a serious P2 Pharma outfit

Very very very good RNS

Why??

NON DILUTIVE FUNDING

What’s been holding this back? Funding

This could literally get absolutely SENT now

Smkr mate thing of going heavy in Sbds, what’s your take on it?

TR1 who took the CLN, close to the company increased from around 7-17% not long ago

Dara Nasr joined the board

EBITDA positive and Q2 cash flow positive

Tiny cap £4m, should have enough cash for a little while. Customers Apple et al

£10m+ revenues with 20%+ growth. Cutting costs too

What du think?

When this really starts shifting, and it will don’t worry about that, our friend Wallace will be absolutely reeling 😂

Exactly. And copper prices rising

That’s literally it. Nothing nothing boring boring ahh what’s going on is it a dud bla bla bla then BOOOOOOOOOOOOM 🚀🚀🚀🚀🚀

It’s just simply too low. The drop was too severe. From 15p to 4p on v good results. A growth story developing. Yes cash need but not 15p to 4p plus Mark Wood now day to day operations - ex CEO FTSE100

Someone needs to ask the question next week - when or are we selling this to Thermo Fisher as per RNS

Potential huge RNS incoming

Edging up

For a company with only a ~£6m market cap, these updates from Ondo InsurTech Plc actually contain a lot of positives.

1. US growth is huge

US revenue rose 115% to £2.3m.

The US is now Ondo’s:

* biggest revenue market

* biggest customer market

* biggest growth driver

That’s a major achievement for a £6m company.

⸻

2. Recurring revenue is surging

Recurring revenue jumped 50% to £3.8m.

That’s important because recurring insurance/software revenue is valued far higher than one-off hardware sales.

The business is becoming:

* more predictable

* more scalable

* higher quality

⸻

3. Big insurer validation

They now have expanding relationships with major insurers including:

* Nationwide

* Liberty Mutual

* Hanover Insurance Group

Nationwide even placed its biggest order yet.

That strongly suggests LeakBot is working commercially.

⸻

4. Scaling without breaking operations

Repairs completed rose 123% yet customer satisfaction still improved.

NPS increased to +88, which is extremely high.

That’s a strong sign the model scales properly.

⸻

5. Contracted revenue already exceeds current revenue

ACRR is now £6.8m versus annual revenue of £4.6m.

That implies:

* more revenue already contracted

* future growth visibility

* deployments still to come

For a £6m market cap, that’s notable.

⸻

Executive Chairman news could be underrated

Greg Wood becoming Executive Chairman looks positive.

He’s former CEO of:

* AXA UK

* Prudential UK

That’s serious insurance-sector experience for a tiny AIM company.

It suggests:

* confidence in the opportunity

* more hands-on leadership

* potentially stronger insurer and funding relationships

Ok defo background buyers at work now

Tidy

“Prior to US FDA approval, laboratories will be introduced to CARDIO inCode-Score® as a Lab Developed Test (LDT)”

As an LDT, the test can be offered through certified laboratories without full FDA device clearance, meaning:

* labs can run the test,

* doctors can order it,

* reimbursement may already apply in some cases,

* and GENI/Thermo can earn from testing activity.

The important thing is this is not just “research use only” wording. They are talking about introducing it commercially into laboratories as a clinical LDT pathway.

That’s also why the ~$500 reimbursement mention is important — they wouldn’t highlight reimbursement if there was no expectation of paid clinical use.

The likely difference is:

* Before FDA: lab-based LDT revenue model

* After FDA: much larger scalable kit/device sales through Thermo Fisher’s network

So FDA approval could massively expand the opportunity, but this announcement implies MONETISATION MAY START EARLIER THAN MANY INVESTORS EXPECTED